Roivant Sciences Ltd. (ROIV)
41.43
+6.50
(+18.61%)
USD |
NASDAQ |
Sep 08, 15:59
41.30
-0.13
(-0.31%)
After-Hours: 20:00
Roivant Sciences Debt to Equity Ratio : 0.0253 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0253 |
| March 31, 2026 | 0.0237 |
| December 31, 2025 | 0.0255 |
| September 30, 2025 | 0.0227 |
| June 30, 2025 | 0.0229 |
| March 31, 2025 | 0.0214 |
| December 31, 2024 | 0.0193 |
| September 30, 2024 | 0.0102 |
| June 30, 2024 | 0.0697 |
| March 31, 2024 | 0.009 |
| December 31, 2023 | 0.0832 |
| September 30, 2023 | 0.525 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.5409 |
| March 31, 2023 | 0.4207 |
| December 31, 2022 | 0.502 |
| September 30, 2022 | 0.4113 |
| June 30, 2022 | 0.3535 |
| March 31, 2022 | 0.1713 |
| December 31, 2021 | 0.1487 |
| September 30, 2021 | 0.1357 |
| June 30, 2021 | 0.1446 |
| March 31, 2021 | 0.1291 |
| March 31, 2020 | 0.089 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Oxford Biomedica Plc | -- |
| Bicycle Therapeutics Plc | 0.0298 |
| Arbutus Biopharma Corp. | 0.014 |
| Moderna, Inc. | 0.1904 |
| Adaptimmune Therapeutics Plc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 5.306B |
| Total Liabilities (Quarterly) | 384.62M |
| Shareholders Equity (Quarterly) | 4.231B |
| Current Ratio | 16.72 |
| Net Debt Paydown Yield | -0.01% |